Vertaling van "al women from uk aged 40-64 " (Nederlands → Frans) :

Gerard et al. Women from UK aged 40-64 (1999) 83 EQ-5D years (eligible for screening) UK tariffs (general population) True negative 0.940 At the breast screening Most women are nervous, but are not anxious or depressed. clinic
At the breast screening Most women are nervous, but are not anxious or depressed. Gerard et al. Women from UK aged 40-64

Table 8: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)
Table 10: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)

The age distribution is somewhat different between men and women. With the latter the progression through the different age groups is almost linear, going from 6% to 16%, with, however, a reduction amongst the 55-64 year-olds (8%).
Chez les hommes, la prévalence de ces troubles est de 4 % chez les personnes de 14 à 34 ans, et se stabilise ensuite autour de 6 % à 7 % jusqu’à 75 ans.

Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK.
Guidelines for the diagnosis and manegement of osteoporosis in postmenopausal women and men from the age of 50 years in the UK.